Pfizer
Brad Szalachowski is a seasoned accounting professional with over 15 years of experience in both corporate and public accounting sectors. Currently serving as Senior Director, Global R&D and BI Divisional Controller at Pfizer since October 2017, Brad previously held the role of Director of Technical Accounting. Prior to joining Pfizer, Brad worked at PwC from September 2008 to October 2017, where contributions included serving as Senior Manager in the National Office's Accounting Services Group, focusing on complex accounting issues like revenue recognition and stock-based compensation. Additionally, Brad's experience includes nearly eight years as Manager in Assurance Services, specializing in audit services for public and private clients in the industrial products and aerospace industries. Brad holds a Master's degree in Accounting and Information Analysis and a Bachelor's degree in Accounting from Lehigh University.
This person is not in any teams
This person is not in any offices
Pfizer
614 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.